← 返回

胰腺癌免疫治疗全球研究趋势的文献计量学分析

英文原题:Bibliometric analysis of global research trends in pancreatic cancer immunotherapy.

查看英文原题

Bibliometric analysis of global research trends in pancreatic cancer immunotherapy.

PubMed 2025/07/24(内容时间) Hum Vaccin Immunother Q2 · IF 4.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺癌是一种高度恶性的肿瘤,预后差且治疗手段有限。免疫治疗在改善预后方面显示出前景,但该领域的文献计量学分析却十分匮乏。我们的工作揭示了新兴趋势,识别了研究空白,并突出了关注点的转变,为免疫治疗的未来研究和临床实践提供了有价值的指导。利用CiteSpace、VOSviewer和RStudio等工具对胰腺癌免疫治疗进行了文献计量学分析,重点关注时空分布、重要作者、研究主题、关键词和引文网络。分析显示,过去十年中胰腺癌免疫治疗的研究活动显著增加,热点包括ICIs、CAR-T 疗法、新型生物标志物、靶向治疗、肿瘤微环境和个性化治疗策略。本研究系统回顾了1991年至2024年胰腺癌免疫治疗的研究进展,突出了关键热点和趋势。未来的努力应集中在ICIs、CAR-T 疗法和联合策略上,以提高疗效并延长患者生存期。

展开英文摘要原文

Pancreatic cancer is a highly malignant tumor with poor prognosis and limited treatments. Immunotherapy shows promise in improving outcomes, but bibliometric analyses in this field are scarce.

Our work reveals emerging trends, identifies research gaps, and highlights shifts in focus, offering valuable guidance for future research of immunotherapy and clinical practice. Pancreatic cancer immunotherapy bibliometric analyses were performed utilizing tools such as CiteSpace, VOSviewer, and RStudio, with a focus on the temporal and spatial distribution, prominent authors, research themes, keywords, and citation networks.

The analysis reveals a significant increase in research activity on pancreatic cancer immunotherapy over the past decade, with hotspots including ICIs, CAR-T therapy, novel biomarkers, targeted therapies, the tumor microenvironment, and personalized treatment strategies.

This study systematically reviews pancreatic cancer immunotherapy research progress from 1991 to 2024, highlighting key hotspots and trends. Future efforts should focus on ICIs, CAR-T therapy, and combination strategies, to enhance outcomes and extend patient survival.

论文信息

作者
Fu T、Chen Y、Wang H、He L、Zhang J、Zhou Y、Duan X、Zhang X
第一作者单位
Department of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.China
通讯作者单位
Clinical Medical Research Center, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Affiliated Wuxi Clinical College of Nantong University, The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Jiangnan University, Wuxi, China.China
文献类型
非美国政府资助研究
期刊
Human vaccines & immunotherapeutics2025 Dec
原文标识
PubMed 40708169 · DOI 10.1080/21645515.2025.2538330